Browsing by Author "Kara M."

Now showing 1 - 12 of 12
  • No Thumbnail Available
    Item
    Comparison of the aerobic contributions to wingate anaerobic tests performed with two different loads
    (1998) Bediz C.Ş.; Gökbel H.; Kara M.; Üçok K.; Çikrikçi E.; Ergene N.
    Background. The purpose of the present study was to compare the aerobic contribution of the Wingate anaerobic test by increasing the test load and power output Methods. Setting: The study was performed in the Physiology Department of the Faculty of Medicine, Selcuk University. Participants: Thirty sedentary male university students Volunteered to this study. Experiments: The subjects performed two Wingate tests against resistance of 75 g·kg-1 and 95 g·kg-1 body weight on Monark 818E bicycle ergometer. Breath-by-breath oxygen consumption rates were measured using an automated metabolic measurement chart (Sensormedics 2900). Aerobic contribution was determined by dividing energy equivalence of net oxygen consumption to the total work. Results. The mean total work values obtained from tests performed at 75 g·kg-1 and 95 g·kg-1 loads were 13.9 ± 1.5 kjoules and 14.5 ± 1.8 kjoules (t=2.32, p = 0.03). Mean total oxygen consumptions were 765 ± 105 ml and 770 ± 110 ml, respectively (t=0.24, p=0.81). Assuming 20% mechanical efficiency for both tests, aerobic contributions were calculated as 19.5 ± 3.7% and 18.9 ± 3.7%, respectively (t=l.01, p=0.30). Conclusions. Although the power outputs of the two tests were different, the difference between aerobic contributions was not statistically significant. So, it was failed to say that the increase in the power outputs might be related to higher contribution of anaerobic processes. However, if different mechanical efficiencies could be used, relationship between aerobic contributions of two tests might have been different.
  • No Thumbnail Available
    Item
    Two new species of Raphignathoidea (Acari: Raphighathidae; Camerobiidae) from Turkey
    (2005) Koç K.; Kara M.
    Two new species Raphignathus ueckermanni sp. n. and Camerobia turcicus sp.n., are described and illustrated from Turkey. A key to the known species of Camerobia is provided.
  • No Thumbnail Available
    Item
    Ultrasonographic measurement of the femoral cartilage thickness in hemiparetic patients after stroke
    (2012) Tunç H.; Öken Ö.; Kara M.; Tiftik T.; Doǧu B.; Ünlü Z.; Özçakar L.
    The aim of the study was to evaluate the femoral cartilage thicknesses of hemiparetic patients after stroke using musculoskeletal ultrasonography and to determine whether there is any correlation between cartilage thicknesses and the clinical characteristics of the patients. Femoral cartilage thicknesses of both knees were measured in 87 (33 women, 54 men) hemiparetic patients. The mean age of the patients was 61.8 years (SD 11.1 years, range 32-87 years) and the mean duration of stroke was 12.3 months (SD 10.5 months, range 1-36 months). The outcome was measured in terms of motor recovery (Brunnstrom stages), spasticity (Modified Ashworth Scale), walking ability (Functional Ambulation Categories), and motor functioning (Functional Independence Measurement instrument). Ultrasonographic measurements were made axially from the suprapatellar window using linear probes while the patients' knees were held in maximum flexion. Three (midpoint) measurements were taken from both knees [lateral condyle (LFC), intercondylar area, and medial condyle (MFC)]. The mean cartilage thicknesses were found to be less on the paretic side (statistically significant only for LFC) when compared with the nonparetic side. Cartilage thickness values were found to be negatively correlated with the duration of immobilization (with paretic side LFC) and BMI (with both sides' MFC) and positively correlated with the Functional Independence Measurement motor score (with paretic side LFC) and the Functional Ambulation Categories scores (with both sides' LFC and MFC). Femoral cartilage is thinner on the paretic side in stroke patients. As the thickness values correlate with the duration of the disease and the ambulatory status of the patients, we suggest that early mobilization would be important in maintaining their cartilage integrity. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.
  • No Thumbnail Available
    Item
    Influence of omega-3 fatty acid on orthodontic tooth movement in rats: A biochemical, histological, immunohistochemical and gene expression study
    (Blackwell Publishing Ltd, 2019) Ogrenim G.; Cesur M.G.; Onal T.; Kara M.; Sirin F.B.; Yalcin G.D.; Inan S.
    Objective: The aim of this study was to investigate the effects of omega-3 fatty acids on orthodontic tooth movement. Setting and Sample Population: For this study, 56 12-week-old adult male Wistar albino rats from the Animal Laboratory at Adnan Menderes University, Faculty of Medicine, were used. Material and Methods: Rats were randomly divided into seven groups (n = 8 each): control group (without any treatment), tooth movement groups (three groups of animals with only tooth movement) and omega groups (three groups of animals with tooth movement and omega-3 administration). Omega-3 fatty acids were administered to the rats systemically during the tooth movement period. On the 3rd, 7th and 14th days after the orthodontic tooth movement, the rats were sacrificed and biochemical, histological, immunohistochemical andgene expression examinations were performed. Results: On the 14th experimental day, the amount of tooth movement in the omega groups was significantly lower than the tooth movement groups (P = 0.012). Biochemical experimentsshowed that the omega groups had significantly lower total oxidant levels and higher total antioxidant levels compared to the tooth movement group on the 14th experimental day (P = 0.001). The levels of RANKL, IL-6 and IL-1β in the omega groups were significantly lower than the tooth movement groups on all experimental days (P < 0.05). Conclusion: Systemic administration of omega-3 fatty acids showed antioxidant and antiinflammatory effects and decelerate the orthodontic tooth movement. © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
  • No Thumbnail Available
    Item
    EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI): Study protocol for a multicentre, observational trial
    (BMJ Publishing Group, 2021) Weiss R.; Saadat-Gilani K.; Kerschke L.; Wempe C.; Meersch M.; Zarbock A.; Makhloufi H.; Cherak A.; Ghanem L.L.; Gouaglia Z.; Guadouri D.N.; Hama F.N.; Kara M.; Saadi O.; Sakhraoui R.; Bourou F.; Cherifi A.; Sadaoui R.G.; Ouyahia A.; Ouahab I.; Bouaoud S.; Abdoun M.; Tidjane A.; Tabeti B.; Boudjenan-Serradj N.; Rivera C.J.P.; Cabrer P.; Corso J.; García J.P.; Idarraga S.; Montoya C.; Figueroa R.; Aldana E.; Torrado M.A.; Peng K.; Ma Z.-M.; Yang Y.-F.; Zhu Y.-J.; Sklienka P.; Frelich M.; Jarkulis V.; Sevcik P.; Vodicka V.; Elbahnasawy M.G.; Elsalhawy S.; Motawea S.; Othman Z.; Sahma M.; Nafea A.M.; Ahmed N.; Attia D.A.; Emara M.M.; Bonna M.M.; Gabr M.A.; Tarbay A.I.; Abdehaleem I.A.; Mohamed E.E.; Eldeeb A.M.; Abbas A.M.; Magdy J.A.; Hamed Z.H.; Osman H.M.E.; Abbas M.S.; Joannes-Boyau O.; Barraud N.; Berthelot C.; Camus T.; Dahmi A.; Defaye M.; Derville S.; El-Boustani Y.; Deloge E.; Jacob H.; Monziols S.; Priem F.; Robin J.-J.; Legros V.; Floch T.; Muccio S.; Geneve C.; Legouge M.L.; Mauny S.T.; Mfam W.; Pascot L.; Aveline C.; Chartier M.; Duteurtre B.; Gautier J.F.; Cousin A.L.; Vautier P.; Nadaud J.; Begel N.; Chekirine C.-A.; Derlon V.; Grein E.; Lehair M.-A.; Magazzeni L.; Magazzeni P.; Potter C.; Roth C.; Voivret F.; Rimmelé T.; Cerro V.; Suria S.; Elmawieh J.; Stoclin A.; Cirenei C.; Andrieu G.; Couloumy S.; Falcone J.; Fajardy M.; Gagneuil A.; Girardet E.; Mazereeuw A.; Ponsonnard S.; Egreteau P.-Y.; Bertel M.; Bocher S.; Carn V.; Guen L.L.; Loup G.L.; Lefevre M.; Ichai C.; Diop A.; Jean-Michel V.; Devlieger S.; Duthoit J.; El Kadiri M.; Léger M.; Cassisa V.; Lasocki S.; Masson C.; Rineau E.; Verrier P.; Coquerel A.; Montravers P.; Atchade E.; Rochon C.-E.; Delerue C.; Quentin V.; Latry V.; Queixalos N.; Cottenceau V.; Braun T.; Bouzoubaa S.; Christ B.; Geiger A.; Gomille J.; Kieffer V.; Mangeant S.; Prochilo C.; Schmitt C.; Skwirba S.; Grand H.; Boury F.; Mayeur N.; Pasquie M.; Garçon P.; Bruckert V.; Arnould V.; Bonciu M.; Chapelle T.; Facchino L.; Fagot-Gandet F.; Iachim A.; Mannu E.; Perus O.; Plattier R.; Rozier R.; Pradel G.; Boudinaud M.; Hausermann M.-H.; Nguyen M.H.; Ramorasata A.; Barreau A.; Boivin A.-H.; Ravry C.; Mottard N.; Beuvelot J.; Bossion F.P.; Desebbe O.; Dörr C.; von Groote T.C.; Küllmar M.; Massoth C.; Ziemann S.; Grüßer L.; Kowark A.; Wittig P.; Brandenburger T.; Dimski T.; Döhmen N.; Huthmann L.; Kaierle D.; Pelletier C.; Schleß M.; Hohn A.; Cleophas S.; Haunhorst S.; Jansen M.; Schmitt A.; Soisch J.; Sturm K.; Rosenberger P.; Bendig A.; Flohr L.; Häberle H.; Hofmann P.; Kuhle J.; Leser N.M.; Pfister K.; Prohaska S.; Sennholz F.; Stetz L.; Weber K.; Stehr S.; Klaus S.; Sadlo M.; Boschin M.; Sengelhoff C.; Göbel U.M.; Haaker J.G.; Göttker C.-K.; Gründel M.; Heringlake M.; Baumgärtel R.; Berggren A.; Gülzow M.; Muras L.; Paarmann H.; Thal S.; Bentley A.; El-Masri D.; Sebastiani A.; Arnaoutoglou E.; Ntalouka M.; Stratigopoulou P.; Analytis A.; Mavrommatis E.; Tzimas P.; Karakosta A.; Pantazi D.; Dimakopoulou A.; Dimitropoulou K.; Ioannidis O.; Jalaawiy H.; Anwar A.; Hashim H.T.; Aldawoody H.I.R.; Cortegiani A.; Catalisano G.; Ingoglia G.; Ippolito M.; De Rosa S.; Cattin L.; Bianchin A.; Barone M.; Paternoster G.; Cutuli S.L.; Russo A.; Sollazzi L.; Cascarano L.; Antonelli M.; Aceto P.; Romanò B.; Spadaro S.; Tripodi V.F.; Rossi M.; Scappatura R.; Vadalà M.C.; Fiume D.; Strano M.T.; Oddo G.; Santorsola C.; Hussain B.A.; Alnaser A.R.; Ghassan A.H.; Hasanein K.; Theab M.; Shin S.; Jung S.; Lee K.; Jung S.M.; Baek J.; Elhadi M.K.; Aldressi W.W.O.; Abuzeid I.; Albaraesi M.; Aldressi S.; Khalel W.; Abdulwahed E.; Abujrad A.A.A.; Almaghrabi A.; Alteleeb M.; Alshareea E.A.A.; Biala M.I.; Deeknah A.; Gheddim D.A.; Ghmagh R.; Ikhrays N.S.A.A.; Sinan M.; Soula E.; Bahroun S.G.; Derwish K.; Mohamed A.M.; Younes E.S.; Al Islam Benjouira R.; Aliwa M.; Altashani N.A.; Alteb M.O.; Msherghi A.; Alagelli F.; Albarouni S.; Albishti A.; Aljamal S.; Alsori M.; Ekhuja T.; Elzwai S.; Ghula M.; Mustafa T.; Tuwaib A.; Zriba H.; Agilla H.M.; Rafanomezantsoa T.A.; Podesta A.M.C.; Bonnici D.M.; Pirotta T.; López G.A.G.; Mijovska M.M.; Davitkovska T.; Gavrilovska A.; Lukikj S.; Vesova M.; Zafirova D.; Amro S.; Hajjaj B.N.F.; Alkhazendar M.; Barakat Y.; Elejla S.A.; Elhissi A.; Khader A.; Salem A.; de Freitas Regufe R.; de Oliveira Eloy A.F.; Perdigão L.M.N.C.; Grigoriev E.; Ivkin A.; Kornelyuk R.; Yaroustovsky M.; Abramyan M.; Komardina E.; Lesteva N.; Aybazova M.; Kumykova E.; Lesina S.; Rybakov G.; Shestov A.; Barmou A.A.A.; Ahmed B.L.A.; Eliyas A.M.; Emadeldin Y.; Kaserer A.; Castellucci C.; Rössler J.; Akbas S.; Petrun A.M.; Gregorcic I.; Sok V.; Cicak R.; Bárcena E.; Guisado A.; Wi I.; Melchor J.R.; Becerra-Bolaños Á.; Cabrera-Doreste S.; Domínguez-Arbelo A.; Delgado-Alonso M.C.; Muiño-Palomar V.; Rodríguez-Pérez A.; Estévez J.M.; Munoz M.B.C.; Matas J.M.; Palao S.P.; Quirós M.D.M.; Teslev A.C.; Argilaga M.; Campos M.; Bainac A.; Batalla A.; Alvarez M.G.; Giné M.; Herránz G.; Hinojal I.; Ejea M.L.; de la Rosa Ruiz N.; Abasolo M.G.; Acuna C.R.H.; Zaranton I.I.; Mendigurenmurua A.; Sanz M.J.M.; de la Fuente E.O.; Vaquero M.P.P.; Iglesias A.S.; Mieres A.U.; Urrestizala A.U.; Ferreira L.; Lobato F.; Sevilla M.A.; Erazo A.; Miró P.; Sabaté S.; Vernetta D.; Perez A.A.; Pagola M.A.; Paulis B.C.; del Val Peciña E.; Odriozola A.G.; Aizpurua A.L.; Piquer O.P.; Garcia P.P.; Rezola P.O.; Lopez A.O.; de la Calle Gil I.; Casado R.N.; Adamove P.; Domenge R.B.; Blasco F.M.B.; Villamizar A.A.R.; Llaneras M.A.P.; García-Sánchez J.I.; Téllez L.F.; Zamorano S.G.; Herreros N.G.; Esteve A.R.; Rodríguez P.M.; Trigo I.G.; Alcaraz A.; Jiménez A.L.; Rubio I.; García N.; Callejas R.; Toha A.M.C.; Claros E.; Cobeta P.; Crespo P.; Dorado T.; Elías E.; Felices J.; Gil D.; Gómez M.; Mané N.; Martín M.; Martínez A.; Pereira L.; Samaranch A.B.N.; Serrano A.; Tiscar C.; VillaHoz J.; Menéndez P.G.; Cardona E.; Conesa A.; Estepa V.; Galán P.; Espí L.L.; Aldeán Y.L.; Manrique S.; Ariza V.M.; Villa L.V.; Suliman E.S.M.A.; Hamid H.; Ibrahim A.M.; Saeed M.M.; Mukadder O.S.; Altun D.; Canbolat N.; Dinçer M.B.; Seyhan T.Ö.; Yildirim S.A.; Iyigün M.; Yapici D.; Özdemir L.; Sagun A.; Boztug N.; Cetintas Y.; Dinc B.; Gündüz E.; Ünlügenç H.; Tunay D.L.; Karakaya D.; Dost B.; Komurcu O.; Akcil E.F.; Dilmen Ö.K.; Tunali Y.; Ok G.; Alsina E.T.; Hakli Ö.; Polat C.; Turgut N.; Kizilcik N.; Köner Ö.; Sen Ö.; Aydin N.; Basaran B.; Bingul E.S.; Gürkan Y.; Darcin K.; Ugur S.; Saracoglu K.T.; Demir A.; Aysegül Ö.; Balci E.; Girgin B.; Guler A.; Karadeniz Ü.; Özaslan N.; Hülya Y.Ö.; Ozcan N.; Postaci A.; Sahap M.; Salman N.; Sagir Ö.; Atik B.; Bicakcioglu M.; Demir H.F.; Fatih U.; Kocaoglu N.; Toprak H.I.; Aslan D.D.; Colak Y.Z.; Ozcan M.S.; Yilmaz M.; Karaca U.; Sahin S.H.; Karka Ö.E.; Senoglu G.D.; Karadag S.E.; Alkis N.; Baytas V.; Akdogan A.; Besir A.; Erturk E.; Kutanis D.; Saylan S.; Tugcugil E.; Ayvat P.; Günaydin B.; Büyükgebiz B.M.; Boran O.F.; Calisir F.; Orak Y.; Balkan B.K.; Büyükcoban S.; Gökel E.; Günenc S.F.; Özbilgin S.; Göre S.; Akesen S.; Cansabuncu S.; Momot N.; Panchenko A.; Pittet J.-F.; Rutledge K.
    Introduction More than 300 million surgical procedures are performed each year. Acute kidney injury (AKI) is a common complication after major surgery and is associated with adverse short-term and long-term outcomes. However, there is a large variation in the incidence of reported AKI rates. The establishment of an accurate epidemiology of surgery-associated AKI is important for healthcare policy, quality initiatives, clinical trials, as well as for improving guidelines. The objective of the Epidemiology of Surgery-associated Acute Kidney Injury (EPIS-AKI) trial is to prospectively evaluate the epidemiology of AKI after major surgery using the latest Kidney Disease: Improving Global Outcomes (KDIGO) consensus definition of AKI. Methods and analysis EPIS-AKI is an international prospective, observational, multicentre cohort study including 10 000 patients undergoing major surgery who are subsequently admitted to the ICU or a similar high dependency unit. The primary endpoint is the incidence of AKI within 72 hours after surgery according to the KDIGO criteria. Secondary endpoints include use of renal replacement therapy (RRT), mortality during ICU and hospital stay, length of ICU and hospital stay and major adverse kidney events (combined endpoint consisting of persistent renal dysfunction, RRT and mortality) at day 90. Further, we will evaluate preoperative and intraoperative risk factors affecting the incidence of postoperative AKI. In an add-on analysis, we will assess urinary biomarkers for early detection of AKI. Ethics and dissemination EPIS-AKI has been approved by the leading Ethics Committee of the Medical Council North Rhine-Westphalia, of the Westphalian Wilhelms-University Münster and the corresponding Ethics Committee at each participating site. Results will be disseminated widely and published in peer-reviewed journals, presented at conferences and used to design further AKI-related trials. Trial registration number NCT04165369. ©
  • No Thumbnail Available
    Item
    Epidemiological, Clinical, and Laboratory Features of Children With COVID-19 in Turkey
    (Frontiers Media S.A., 2021) Karbuz A.; Akkoc G.; Bedir Demirdag T.; Yilmaz Ciftdogan D.; Ozer A.; Cakir D.; Hancerli Torun S.; Kepenekli E.; Erat T.; Dalgic N.; Ilbay S.; Karaaslan A.; Erdeniz E.H.; Aygun F.D.; Bozdemir S.E.; Hatipoglu N.; Emiroglu M.; Sahbudak Bal Z.; Ciftci E.; Bayhan G.I.; Gayretli Aydin Z.G.; Ocal Demir S.; Kilic O.; Hacimustafaoglu M.; Sener Okur D.; Sen S.; Yahsi A.; Akturk H.; Cetin B.; Sutcu M.; Kara M.; Uygun H.; Tural Kara T.; Korukluoglu G.; Akgun O.; Üstündağ G.; Demir Mis M.; Sali E.; Kaba O.; Yakut N.; Kılıc O.; Kanik M.K.; Cetin C.; Dursun A.; Cicek M.; Kockuzu E.; Sevketoglu E.; Alkan G.; Guner Ozenen G.; İnce E.; Baydar Z.; Ozkaya A.K.; Ovali H.F.; Tekeli S.; Celebi S.; Cubukcu B.; Bal A.; Khalilova F.; Kose M.; Hatipoglu H.U.; Dalkiran T.; Turgut M.; Basak Altas A.; Selcuk Duru H.N.; Aksay A.; Saglam S.; Sari Yanartas M.; Ergenc Z.; Akin Y.; Duzenli Kar Y.; Sahin S.; Tuteroz S.K.; Bilen N.M.; Ozdemir H.; Senoglu M.C.; Pariltan Kucukalioglu B.; Besli G.E.; Kara Y.; Turan C.; Selbest Demirtas B.; Celikyurt A.; Cosgun Y.; Elevli M.; Sahin A.; Bahtiyar Oguz S.; Somer A.; Karadag B.; Demirhan R.; Turk Dagi H.; Kurugol Z.; Taskin E.C.; Sahiner A.; Yesil E.; Ekemen Keles Y.; Sarikaya R.; Erdem Eralp E.; Ozkinay F.; Konca H.K.; Yilmaz S.; Gokdemir Y.; Arga G.; Ozen S.; Coksuer F.; Vatansever G.; Tezer H.; Kara A.
    Objectives: The aim of this study is to identify the epidemiological, clinical, and laboratory features of coronavirus disease 2019 (COVID-19) in children. Methods: A retrospective study was conducted by pediatric infectious disease specialists from 32 different hospitals from all over Turkey by case record forms. Pediatric cases who were diagnosed as COVID-19 between March 16, 2020, and June 15, 2020 were included. Case characteristics including age, sex, dates of disease onset and diagnosis, family, and contact information were recorded. Clinical data, including the duration and severity of symptoms, were also collected. Laboratory parameters like biochemical tests and complete blood count, chest X-ray, and chest computed tomography (CT) were determined. Results: There were 1,156 confirmed pediatric COVID-19 cases. In total, male cases constituted 50.3% (n = 582) and females constituted 49.7% (n = 574). The median age of the confirmed cases was 10.75 years (4.5–14.6). Of the total cases, 90 were younger than 1 year of age (7.8%), 108 were 1–3 years of age (9.3%), 148 were 3–6 years of age (12.8%), 298 were 6–12 years of age (25.8%), 233 were 12–15 years of age (20.2%), and 268 cases were older than 15 years of age (23.2%). The most common symptom of the patients at the first visit was fever (50.4%) (n = 583) for a median of 2 days (IQR: 1–3 days). Fever was median at 38.4°C (38.0–38.7°C). The second most common symptom was cough (n = 543, 46.9%). The other common symptoms were sore throat (n = 143, 12.4%), myalgia (n = 141, 12.2%), dyspnea (n = 118, 10.2%), diarrhea (n = 112, 9.7%), stomachache (n = 71, 6.1%), and nasal discharge (n = 63, 5.4%). When patients were classified according to disease severity, 263 (22.7%) patients were asymptomatic, 668 (57.7%) patients had mild disease, 209 (18.1%) had moderate disease, and 16 (1.5%) cases had severe disease. One hundred and forty-nine (12.9%) cases had underlying diseases among the total cases; 56% of the patients who had severe disease had an underlying condition (p < 0.01). The need for hospitalization did not differ between patients who had an underlying condition and those who do not have (p = 0.38), but the need for intensive care was higher in patients who had an underlying condition (p < 0.01). Forty-seven (31.5%) of the cases having underlying conditions had asthma or lung disease (38 of them had asthma). Conclusions: To the best of our knowledge, this is one of the largest pediatric data about confirmed COVID-19 cases. Children from all ages appear to be susceptible to COVID-19, and there is a significant difference in symptomatology and laboratory findings by means of age distribution. © Copyright © 2021 Karbuz.
  • No Thumbnail Available
    Item
    A New Approach on Some Special Curves
    (Association of Mathematicians (MATDER), 2023) Aydın T.A.; Kocayiğit H.; Kara M.
    In this paper, we obtain some characterizations for a Frenet curve with the help of an alternative frame different from the Frenet frame. Also, in the present study, we consider weak biharmonic and harmonic 1-type curves by using the mean curvature vector field of the curve. We also study 1-type and biharmonic curves whose mean curvature vector field is in the kernel of Laplacian. We give some theorems for such curves in the Euclidean 3-space. Moreover, we give the classifications of these types of curves. © MatDer.
  • No Thumbnail Available
    Item
    A snapshot of pediatric inpatients and outpatients with COVID-19: a point prevalence study from Turkey
    (Springer Science and Business Media Deutschland GmbH, 2023) Yılmaz D.; Üstündağ G.; Büyükçam A.; Salı E.; Çelik Ü.; Avcu G.; Belet N.; Çakmak Taşkın E.; Öcal Demir S.; Birbilen A.Z.; Kılıç Ö.; Metin Akcan Ö.; Tekin Yılmaz A.; Aldemir Kocabaş B.; Hatipoğlu N.; Karbuz A.; Çakır D.; Sütçü M.; Aygün F.D.; Çelik T.; Bayturan Şen S.; Dalgıç N.; Ümit Z.; Kara S.S.; Karadağ Öncel E.; Bolat A.; Kılıç Çil M.; Turan C.; Çakıl Güzin A.; Topal S.; Esen Besli G.; Doğan G.; Şahin S.; Akın F.; Bildirici Y.; Timurtaş Dayar G.; Ergül Sarı E.; Kızmaz İşançlı D.; Kara M.; Önal P.; Aylaç H.; Lüleci D.; Yaşar B.; Dede E.; Çağlar A.; Akova S.; Afat Turgut E.; Yazıcı Özkaya P.; Kandemir Gülmez T.; Ulusoy E.; Duyu M.; Kara Y.; Çeliktaş H.; Tekeli O.; Çağlar F.; Gül D.; Oral Cebeci S.; Battal F.; Bal A.; Aygün E.; Uysalol M.; Arslan G.; Özkavaklı A.; Kızıl M.C.; Yazar A.; Aygün F.; Somer A.; Kuyucu N.; Dinleyici E.Ç.; Kara A.
    This multi-center point prevalence study evaluated children who were diagnosed as having coronavirus disease 2019 (COVID-19). On February 2nd, 2022, inpatients and outpatients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included in the study from 12 cities and 24 centers in Turkey. Of 8605 patients on February 2nd, 2022, in participating centers, 706 (8.2%) had COVID-19. The median age of the 706 patients was 92.50 months, 53.4% were female, and 76.7% were inpatients. The three most common symptoms of the patients with COVID-19 were fever (56.6%), cough (41.3%), and fatigue (27.5%). The three most common underlying chronic diseases (UCDs) were asthma (3.4%), neurologic disorders (3.3%), and obesity (2.6%). The SARS-CoV-2-related pneumoniae rate was 10.7%. The COVID-19 vaccination rate was 12.5% in all patients. Among patients aged over 12 years with access to the vaccine given by the Republic of Turkey Ministry of Health, the vaccination rate was 38.7%. Patients with UCDs presented with dyspnea and pneumoniae more frequently than those without UCDs (p < 0.001 for both). The rates of fever, diarrhea, and pneumoniae were higher in patients without COVID-19 vaccinations (p = 0.001, p = 0.012, and p = 0.027). Conclusion: To lessen the effects of the disease, all eligible children should receive the COVID-19 vaccine. The illness may specifically endanger children with UCDs. What is Known: • Children with COVID-19 mainly present with fever and cough, as in adults. • COVID-19 may specifically threaten children with underlying chronic diseases. What is New: • Children with obesity have a higher vaccination rate against COVID-19 than children without obesity. • Among unvaccinated children, fever and pneumoniae might be seen at a higher ratio than among vaccinated children. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
  • No Thumbnail Available
    Item
    Antibiotic associated diarrhea in outpatient pediatric antibiotic therapy
    (BioMed Central Ltd, 2023) Tanır Basaranoğlu S.; Karaaslan A.; Salı E.; Çiftçi E.; Gayretli Aydın Z.G.; Aldemir Kocabaş B.; Kaya C.; Şen Bayturan S.; Kara S.S.; Yılmaz Çiftdoğan D.; Çay Ü.; Gundogdu Aktürk H.; Çelik M.; Ozdemir H.; Somer A.; Diri T.; Yazar A.S.; Sütçü M.; Tezer H.; Karadag Oncel E.; Kara M.; Çelebi S.; Özkaya Parlakay A.; Karakaşlılar S.; Arısoy E.S.; Tanır G.; Tural Kara T.; Devrim İ.; Erat T.; Aykaç K.; Kaba Ö.; Güven Ş.; Yeşil E.; Tekin Yılmaz A.; Yaşar Durmuş S.; Çağlar İ.; Günay F.; Özen M.; Dinleyici E.Ç.; Kara A.
    Background: Antibiotic-associated diarrhea is one of the most frequent side effects of antimicrobial therapy. We assessed the epidemiological data of antibiotic-associated diarrhea in pediatric patients in our region. Methods: The prospective multi-center study included pediatric patients who were initiated an oral antibiotic course in outpatient clinics and followed in a well-established surveillance system. This follow-up system constituded inclusion of patient by the primary physician, supply of family follow-up charts to the family, passing the demographics and clinical information of patient to the Primary Investigator Centre, and a close telephone follow-up of patients for a period of eight weeks by the Primary Investigator Centre. Results: A result of 758 cases were recruited in the analysis which had a frequency of 10.4% antibiotic-associated diarrhea. Among the cases treated with amoxicillin-clavulanate 10.4%, and cephalosporins 14.4% presented with antibiotic-associated diarrhea. In the analysis of antibiotic-associated diarrhea occurrence according to different geographical regions of Turkey, antibiotic-associated diarrhea episodes differed significantly (p = 0.014), particularly higher in The Eastern Anatolia and Southeastern Anatolia. Though most commonly encountered with cephalosporin use, antibiotic-associated diarrhea is not a frequent side effect. Conclusion: This study on pediatric antibiotic-associated diarrhea displayed epidemiological data and the differences geographically in our region. © 2023, The Author(s).
  • No Thumbnail Available
    Item
    SARcopenia Assessment in Hypertension
    (Lippincott Williams and Wilkins, 2023) Kara M.; Kara Ö.; Ceran Y.; Kaymak B.; Kaya T.C.; Çıtır B.N.; Durmuş M.E.; Durmuşoğlu E.; Razaq S.; Doğan Y.; Shehab D.; Alkandari S.A.; Abdulsalam A.J.; Ata A.M.; Koyuncu E.G.; Coşkun E.; Turan G.; Dilek B.; Culha M.A.; Yıldırım P.; Mezian K.; Doğu B.; Kılıç G.; Ünlü Z.; Barbosa J.; Pinho S.; Analay P.; Palamar D.; Güvener O.; Ocak H.; Malas F.Ü.; Baday M.; Çakır B.; Özçakar L.
    Objectives: The aims of the study were to investigate the relationship between sarcopenia and renin-angiotensin system-related disorders and to explore the effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on muscle mass/function and physical performance. Design: This multicenter, cross-sectional study was performed using ISarcoPRM algorithm for the diagnosis of sarcopenia. Results: Of the 2613 participants (mean age = 61.0 ± 9.5 yrs), 1775 (67.9%) were hypertensive. All sarcopenia-related parameters (except chair stand test in males) were worse in hypertensive group than in normotensive group (all P < 0.05). When clinical/potential confounders were adjusted, hypertension was found to be an independent predictor of sarcopenia in males (odds ratio = 2.403 [95% confidence interval = 1.514-3.813]) and females (odds ratio = 1.906 [95% confidence interval = 1.328-2.734], both P < 0.001). After adjusting for confounding factors, we found that all sarcopenia-related parameters (except grip strength and chair stand test in males) were independently/negatively related to hypertension (all P < 0.05). In females, angiotensin-converting enzyme inhibitors users had higher grip strength and chair stand test performance values but had lower anterior thigh muscle thickness and gait speed values, as compared with those using angiotensin II receptor blockers (all P < 0.05). Conclusions: Hypertension was associated with increased risk of sarcopenia at least 2 times. Among antihypertensives, while angiotensin-converting enzyme inhibitors had higher muscle function values, angiotensin II receptor blockers had higher muscle mass and physical performance values only in females. © 2022 Wolters Kluwer Health, Inc.
  • No Thumbnail Available
    Item
    The Relationship Among Probable SARCopenia, Osteoporosis and SuprasPinatus Tendon Tears in Postmenopausal Women: The SARCOSP Study
    (Springer, 2024) Kara M.; Kara Ö.; Durmuş M.E.; Analay P.; Şener F.E.; Çıtır B.N.; Korkmaz G.O.; Ünlü Z.; Tiftik T.; Gürçay E.; Mülkoğlu C.; Yalçınkaya B.; Bağcıer F.; Aksakal M.F.; Erdoğan K.; Sertçelik A.; Çakır B.; Kaymak B.; Özçakar L.
    We aimed to investigate the relationship among probable sarcopenia, osteoporosis (OP) and supraspinatus tendon (SSP) tears in postmenopausal women. Postmenopausal women screened/followed for OP were recruited. Demographic data, comorbidities, exercise/smoking status, and handgrip strength values were recorded. Probable sarcopenia was diagnosed as handgrip strength values < 20 kg. Achilles and SSP thicknesses were measured using ultrasound. Among 1443 postmenopausal women, 268 (18.6%) subjects had SSP tears. Unilateral tears were on the dominant side in 146 (10.1%) and on the non-dominant side in 55 women (3.8%). In contrast to those without, women with SSP tears had older age, lower level of education, thinner SSP and lower grip strength (all p < 0.05). In addition, they had higher frequencies of hypertension, hyperlipidemia, DM, OP and probable sarcopenia, but lower exercise frequency (all p < 0.05). Binary logistic regression modeling revealed that age [odds ratio (OR): 1.046 (1.024–1.067 95% CI)], hypertension [OR: 1.560 (1.145–2.124 95% CI)], OP [OR: 1.371 (1.022–1.839 95% CI)] and probable sarcopenia [OR: 1.386 (1.031–1.861 95% CI)] were significant predictors for SSP tears (all p < 0.05). This study showed that age, presence of hypertension, probable sarcopenia and OP were related with SSP tears in postmenopausal women. To this end, although OP appeared to be related to SSP tears, SSP tear/thickness evaluation can be recommended for OP patients, especially those who have other risk factors such as older age, higher BMI, hypertension, and probable sarcopenia. © The Author(s) 2024.
  • No Thumbnail Available
    Item
    Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study
    (Multidisciplinary Digital Publishing Institute (MDPI), 2025) Tünbekici S.; Yuksel H.C.; Acar C.; Sahin G.; Orman S.; Majidova N.; Coskun A.; Seyyar M.; Dilek M.S.; Kara M.; Dıslı A.K.; Demir T.; Kolkıran N.; Sahbazlar M.; Demırcıler E.; Kuş F.; Aytac A.; Menekse S.; Yucel H.; Biter S.; Koseci T.; Unsal A.; Ozveren A.; Sevınc A.; Goker E.; Gürsoy P.
    Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18–67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23–2.75) and a median overall survival of 4.1 months (95% CI: 3.52–4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0–1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies. © 2024 by the authors.